Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma
Open Access
- 16 August 2016
- journal article
- research article
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 9 (1) , 1-8
Abstract
Cytogenetic abnormalities are important prognostic markers in plasma cell myeloma (PCM) and detection is routinely performed by interphase fluorescence in-situ hybridization (FISH) with a panel of probes after enrichment of the plasma cells in the bone marrow specimen. Cell sorting by immunomagnetic beads and concurrent labeling of the cytoplasmic immunoglobulin are the usual enrichment methods. We present an alternative method of plasma cell enrichment termed Target FISH, which is an automated system that combines the images of May-Grünwald- Giemsa (MGG) staining and FISH study on the same plasma cell for analysis. Our experience of Target FISH on 40 PCM patients was described. Briefly, plasma cells were MGG stained, image captured, de-stained, FISH probe hybridized and finally relocated for simultaneous analysis of morphology and FISH signal pattern. The FISH probe panel was TP53/CEP17, t(4;14) IGH/FGFR3, t(14;16) IGH/MAF and CKS1B(1q21)/CDKN2C(P18). Gain of 1q21 was the most common abnormality detected in 18 patients (45 %), to be followed by t(4;14) IGH/FGFR3 detected in 11 patients (27.5 %). Of note, 10 patients showed coexistence of both t(4;14) and 1q21 gain. Two patients showed del(17p)/TP53, one in association with t(4;14) and 1q gain while the other was stand alone. None of this patient cohort showed t(14;16) IGH/MAF. Using the critical binomial function, the normal cutoff FISH positive value for del(17p)/TP53 was 3.4 %, t(4;14) IGH/FGFR3 was 6.8 %, t(14;16) IGH/MAF was 5.6 % and +1q21 was 5.7 %. The equipment cost notwithstanding, when compared with cell sorting, the total reagent cost was around 10 % lower in Target FISH. The total processing time was longer for Target FISH but manual fluorescence microscopy was no longer necessary. The main advantage of Target FISH was the complete certainty that the cytogenetic abnormality was detected in the cells of interest, and hence a more stringent analytical cutoff value might be considered. Optimization of the cell collection and slide preparation process upfront was required to accrue adequate target cells on each slide for analysis. Our experience suggested that Target FISH was applicable as a routine method of plasma cell enrichment in clinical diagnostic laboratories.Keywords
This publication has 23 references indexed in Scilit:
- Modified cIg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practiceCancer Genetics, 2014
- IMWG consensus on risk stratification in multiple myelomaLeukemia, 2013
- Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in SingaporeChinese Medical Journal, 2013
- Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.2012
- Application of an immune‐magnetic cell sorting method for CD138‐positive plasma cells in FISH analysis of multiple myelomaInternational Journal of Laboratory Hematology, 2012
- Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disordersHaematologica, 2012
- Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients.2011
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011
- Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridizationCancer Genetics and Cytogenetics, 2005
- Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization.1995